1. Home
  2. FGBI vs STTK Comparison

FGBI vs STTK Comparison

Compare FGBI & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FGBI
  • STTK
  • Stock Information
  • Founded
  • FGBI 1934
  • STTK 2016
  • Country
  • FGBI United States
  • STTK United States
  • Employees
  • FGBI N/A
  • STTK N/A
  • Industry
  • FGBI Savings Institutions
  • STTK Biotechnology: Pharmaceutical Preparations
  • Sector
  • FGBI Finance
  • STTK Health Care
  • Exchange
  • FGBI Nasdaq
  • STTK Nasdaq
  • Market Cap
  • FGBI 122.8M
  • STTK 112.6M
  • IPO Year
  • FGBI N/A
  • STTK 2020
  • Fundamental
  • Price
  • FGBI $8.93
  • STTK $2.65
  • Analyst Decision
  • FGBI
  • STTK Hold
  • Analyst Count
  • FGBI 0
  • STTK 6
  • Target Price
  • FGBI N/A
  • STTK $2.67
  • AVG Volume (30 Days)
  • FGBI 7.8K
  • STTK 411.6K
  • Earning Date
  • FGBI 10-30-2025
  • STTK 11-13-2025
  • Dividend Yield
  • FGBI 0.45%
  • STTK N/A
  • EPS Growth
  • FGBI N/A
  • STTK N/A
  • EPS
  • FGBI N/A
  • STTK N/A
  • Revenue
  • FGBI $59,070,000.00
  • STTK $2,997,000.00
  • Revenue This Year
  • FGBI N/A
  • STTK N/A
  • Revenue Next Year
  • FGBI $0.20
  • STTK N/A
  • P/E Ratio
  • FGBI N/A
  • STTK N/A
  • Revenue Growth
  • FGBI N/A
  • STTK N/A
  • 52 Week Low
  • FGBI $6.56
  • STTK $0.69
  • 52 Week High
  • FGBI $15.25
  • STTK $2.71
  • Technical
  • Relative Strength Index (RSI)
  • FGBI 67.11
  • STTK 75.66
  • Support Level
  • FGBI $7.85
  • STTK $2.29
  • Resistance Level
  • FGBI $8.25
  • STTK $2.48
  • Average True Range (ATR)
  • FGBI 0.15
  • STTK 0.22
  • MACD
  • FGBI 0.09
  • STTK -0.01
  • Stochastic Oscillator
  • FGBI 93.91
  • STTK 100.00

About FGBI First Guaranty Bancshares Inc.

First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: